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Abstract
Background: The benefits of statin therapy are significantly compromised by noncompliance. Although elderly patients may
have particular challenges with medication adherence and persistence, previous reviews on statin adherence have not focused on
this population. Additionally, comparisons of adherence and persistence specific to statin indication (primary or secondary
prevention) have not been thoroughly explored.
Objective: We aim to assess the extent of, and factors associated with, adherence and persistence to statin therapy among older
populations (aged ≥65 years).
Methods: A systematic review will be undertaken according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses recommendations. Searches will be performed using multiple electronic databases (Ovid MEDLINE, EMBASE,
PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, and the
National Health Service Economic Evaluation Database) to identify relevant randomized trials and observational studies that
evaluated statin adherence and/or persistence as an outcome. Eligible studies will include those involving community-living or
outpatient elderly individuals. The methodological quality of randomized controlled trials (RCTs) will be assessed via the Joanna
Briggs Institute’s critical appraisal checklist for RCTs, and the quality assessment of observational studies will be undertaken
using a set of questions formulated with resort to the National Institute of Health Quality Assessment Tool for Observational
Cohort and Cross-Sectional Studies. When possible, meta-analyses will be conducted using random-effect modeling and generic
inverse variance analyses for adjusted-effect estimates. Heterogeneity across studies will be quantified using the I2 statistic. The
presence of publication bias will be assessed using funnel plots and Egger’s regression tests. A leave-one-out sensitivity analysis
will also be conducted to assess the impact of individual study results on pooled estimates. To explore possible sources of
heterogeneity across studies, subgroup analyses will be performed based on covariates such as study design, statin indication,
country of study, and length of patient follow-up.
Results: The electronic database searches were completed in December 2016. Retrieved articles are currently being screened
and the entire study is expected to be completed by June 2017.
Conclusions: This systematic review will provide further understanding of the patterns of, and barriers to, statin adherence and
persistence among older patients. The findings will inform clinical practice and the design of appropriate interventions.
Trial Registration: PROSPERO CRD42016053191
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Introduction
Beginning with their discovery in the 1970s, and becoming
available for clinical use in the 1980s [1], 3-
hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) are one of the most frequently
prescribed medications, with global users estimated to be more
than 1 billion in 2014 [2]. Several clinical trials and reviews
have reported statins to be highly efficacious for the prevention
of cardiovascular events [3,4]. The biological role of statins in
the reduction of cholesterol levels has also led to suggestions
of possible use of statins as preventive agents for other
conditions, such as dementia [5] and cancer prevention [6,7].
Statins are generally well tolerated by most patients [8], but
nonadherence has been reported across observational studies
and from analyses of large population-based registries [9]. A
meta-analysis estimated that only approximately half (49%) of
all patients in observational studies were adherent to statin
therapy at 1 year of follow-up [10], although much higher
adherence (90.3%) has been observed in randomized trials [10],
in which participants were often motivated, and rigorous
follow-up was usually in place.
Furthermore, studies have demonstrated increased risk of
adverse outcomes following poor statin adherence [11-13]. In
some cases, outcomes among nonadherers and those who
discontinued statin therapy were found to be even worse than
for those who had not initiated treatment [13].
Several systematic reviews have been published on adherence
among statin users [9,14,15]. However, no reviews have focused
on elderly patients who may face unique challenges with
adherence and persistence, especially since this group
experiences greater comorbidity and polypharmacy, which are
two key contributing factors to these phenomona [16-18].
Additionally, the balance of the risks and benefits associated
with statin therapy (particularly for primary prevention) remains
unclear and highly debated for the elderly [19,20]. These factors
may further impact on patients’ willingness to adhere to
treatment.
Ongoing demographic changes, characterized by an increasing
number of elderly individuals [21], suggests that this population
will constitute a significant proportion of current and future
statin users. In light of this reality, a systematic review that
seeks to explore issues of adherence and persistence specific to
the older population is necessary to: (1) identify relevant
barriers, (2) compare the level of adherence and persistence
relative to statin indication (primary or secondary prevention),
and (3) inform the design of appropriate interventions.
Methods
This systematic review will be carried out in line with
recommendations specified in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [22]. The protocol has also been prepared in
accordance with PRISMA Protocols guidelines (Supplemental
File 1) [23].
Review Objectives
This study will assess the extent of, and factors associated with,
adherence and persistence to statin therapy among older
populations. More specifically, the review objectives are:
• To quantify the proportion of older statin users who are
adherent, and compare rates reported in randomized trials
to those reported in observational studies, as well as by
statin indication (primary vs secondary prevention).
• To assess the level of persistence to statin therapy among
older patients, and compare rates between primary and
secondary prevention patients.
• To assess, summarize, and provide estimates of risk
indicators associated with nonadherence and nonpersistence
to statin therapy in the elderly.
The key components of the review will follow the standard
population, intervention, comparison, outcome, and study design
(PICOS) approach (Textbox 1) [24].
Textbox 1. Key components of the systematic review following the standard PICOS approach.
• Population: older patients (aged ≥65 years) undergoing primary or secondary prevention treatment
• Intervention: all statins (HMG-CoA reductase inhibitors)
• Comparison: none
• Outcomes: proportion of patients who were adherent, proportion of patients who were persistent at predefined periods, risk factors associated
with nonadherence, risk factors associated with nonpersistence
• Study design: randomized controlled trials and observational studies (prospective and retrospective)
Intervention
The study will focus on all statins and will consider their use
for primary and secondary prevention among elderly
populations. The outcome(s) evaluated will not be compared
across the different statins, and comparisons related to dosing
regimen (eg, once or twice daily dosing) will not be carried out.
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Outcomes
The use or nonuse of prescribed medicines by patients is often
described using a variety of terms such as adherence,
compliance, persistence, or concordance, which can cause
confusion [25-27]. Nonetheless, adherence, compliance, and
concordance are often used in relation to instances involving
medication doses that are missed [28], and persistence is often
used in relation to the time from initiation to termination of
treatment [29]. Medication concordance, conversely, is usually
used to emphasize that the doctor and patient have achieved
some level of agreement regarding the therapeutic goal(s) [30].
For this review, adherence and compliance will represent the
same thing, and be used interchangeably. When reference is
made to persistence, this will relate to the duration of statin use.
The benefits of statin therapy are likely to accrue over time [31],
making persistence an important measure that is closely related
to adherence. Adherence and persistence are detailed below.
Adherence
Adherence refers to, “the extent to which a patient acts in
accordance with the prescribed interval and dose of a dosing
regimen” [29]. At the individual level, adherence may be
estimated via the proportion of doses taken (PDT), which is
calculated as: (number of pills taken in time Y)/ (number of pill
prescribed for time Y)*100 [32]. Adherence may also be
expressed as the proportion of days covered (PDC) which is
calculated as: (total days drugs available)/(days in follow-up
period)*100 [33]. Furthermore, adherence may be quantified
in terms of the medicines possession ratio (MPR) which is
calculated as: (number of days of medication supplied within
refill interval)/(number of days in refill interval)*100] [33]. In
this review, we will define adequate adherence to represent
instances in which the MPR, PDC, and PDT are each
≥80%[10,14]. As such, for studies adopting the MPR, PDC,
PDT, and similar methodologies, we will only include those
that report sample-level adherence rates based on the application
of the ≥80% threshold to individual patients. Studies that
measure adherence as a continuous (rather than dichotomous)
variable using MPR, PDC, PDT, and similar methodologies
will be excluded. Studies that utilize other tools, including
self-reported scales (eg, Morisky Medication Adherence Scale
[34]), and classify patients as adherent will use the tool’s
established recommendations. Of note, adherence rates in this
review will not include primary nonadherence, which indicates
instances that patients failed to fill their first statin prescription
[35].
Persistence
Persistence refers to the continuous use of medication by patients
for the required duration. Although various methods exist for
estimating medication persistence, including the use of
medication possession at a fixed point in time, the most
commonly adopted approach involves quantifying the gaps
between prescription refills [36]. Patients are often considered
to have discontinued (been nonpersistent) if they have exceeded
a permissible gap (number of days allowed between refills). No
standardized permissible gap typically exists, as this will often
be dictated by the length of previous prescriptions. However, a
range of 1.5-3 times the days’ supply of preceding prescription
has often been used [37]. We will consider all studies that report
sample-level persistence rates, whether based on a defined
permissible gap or where there is evidence of discontinuation,
such as patient self-reports.
This study will also assess factors that are reported to influence
adherence and persistence to statin therapy among elderly
patients. These factors will be grouped under five themes, in
line with the World Health Organization’s classification of
predictive factors of nonadherence [38,39]: (1) patient-related
factors (eg, gender), (2) socioeconomic factors (eg, educational
status, family support), (3) therapy-related factors (eg,
concurrent drug therapy, adverse effects), (4) health
system-related factors (eg, proximity to pharmacy), and (5)
disease-related factors (eg, presence of comorbidities).
Study Inclusion and Exclusion Criteria
For the current review, both observational (prospective and
retrospective) studies and randomized controlled trials (RCTs)
that evaluated statin adherence and/or persistence as an outcome
will be included. In line with similar reviews [28], we will focus
on noninstitutionalized persons and will exclude studies
conducted solely on participants within nursing or care homes
and inpatient settings. Studies in which medications were
administered by a carer or healthcare personnel will be excluded
[28]. For studies to be eligible, adherence and/or persistence
should also have been assessed over a defined period using an
objective measure (eg, pill count, medication refill data) or via
a validated self-reported instrument. Studies that mixed older
(≥65 years years) and younger individuals (<65 years) will be
excluded unless specific results have been presented for the
elderly population, or where efforts to retrieve such data from
authors have been successful. Studies that do not report
adherence and/or persistence solely on statins (eg, where statins
are mixed with other medications including other lipid-lowering
drugs) will be excluded. Studies with sample sizes <50 will be
excluded [40]. No country restrictions will be imposed.
Search Strategy
To identify appropriate studies for the review, searches were
performed using Ovid MEDLINE, EMBASE, CINAHL,
PsycINFO, Database of Abstracts of Reviews of Effects,
National Health Service Economic Evaluation Database, and
the Cochrane Central Register of Controlled Trials. The main
keywords that were used included, “statins or HMG-CoA
reductase inhibitors or individual generic and propriety names”
and, “medication compliance or adherence or persistence or
treatment refusal or drop out or discontinuation”. Table 1
presents the search strategy for Ovid MEDLINE developed in
consultation with an information management specialist
(librarian) [41]. This search strategy was replicated for the
remaining databases, and modifications were made in-line with
individual database requirements if necessary. All electronic
searches were completed on December 12, 2016 and only studies
published before this date will be considered for inclusion in
this review. The reference list of all selected articles will be
screened for additional studies. In view of limited time and
resources, only studies published in English will be considered
for the review.
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Table 1. Search strategy developed for Ovid MEDLINE.
Block 1: Statins
1. exp hydroxymethylglutaryl-coA reductase inhibitors/
2. statin*.mp.
3. ([hmg-coa reductase or hydroxymethylglutaryl coa or hydroxymethylglutaryl-coenzyme
a] adj2 inhibit*).mp.
4. (atorvastatin or lipitor).mp.
5. (simvastatin or zocor).mp.
6. (cerivastatin or lipobay or baychol).mp.
7. (lovastatin or mevacor or altoprev).mp.
8. (fluvastatin or lescol).mp.
9. mevastatin.mp.
10. (rosuvastatin or crestor).mp.
11. (pitavastatin or livalo).mp.
12. (pravastatin or pravachol).mp.
13. ([lipid or cholesterol] adj3 lower*).mp.
14. (antilipid* or anti-lipid*).mp.
15. or/1-14
Block 2: Adherence/compliance/persistence
16. exp patient compliance/
17. exp medication adherence/
18. (complian* or noncomplian* or discontinu* or adher* or persist* or concordance or non-
adher* or nonpersist* or dropout* or drop-out*).mp.
19. (patient* adj3 [attitude* or acceptance* or satisf*]).mp.
20. (treatment* adj3 [stop* or abandon* or refus*]).mp.
21. or/16-20
Block 3: Study designs
22. ([observation* or prospective* or retrospective*] adj2 [study or studies]).mp.
23. randomized controlled trial.pt.
24. controlled clinical trial.pt.
25. randomized.ab.
26. placebo.ab.
27. drug therapy.fs.
28. trial.ab
29. groups.ab.
30. or/22-29
Search hits
31. 15 and 21 and 30
Limits
32. exp animals/not humans.sh.
33. 31 not 32
34. limit 33 to English language
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Study Selection
Results of individual database searches will be exported to
Endnote referencing software and duplicates will be removed.
Titles and abstracts of studies will initially be screened, and
those that are likely to be of interest and relevance will be
shortlisted for full-text examination. The full-text assessment
will be undertaken with consideration of the study
inclusion/exclusion criteria. We will link studies with multiple
publications. The study-screening process will be conducted by
RO and validated by another member of the team.
Disagreements will involve consultation with a third team
member and any issues will be addressed using a
consensus-based approach. The entire screening and selection
process will be summarized using a PRISMA flow chart and
reasons for exclusion of studies will be documented.
Study Quality Appraisal
The methodological quality of RCTs will be assessed using the
Joanna Briggs Institute’s critical appraisal checklist for RCTs
(Supplemental File 2) [42]. This tool includes 13 questions that
relate to randomization, allocation concealment, blinding, and
data analysis. For observational studies, quality assessments
will be undertaken using a set of questions formulated with
resort to the National Institutes of Health (NIH) Quality
Assessment Tool for Observational Cohort and Cross-Sectional
Studies (Supplemental File 3) [43]. The NIH tool includes 14
questions that relate to reporting, sample size estimation,
loss-to-follow-up, outcome measurement, validity, and
generalizability. The quality of each study will be rated as either
good, fair, or poor.
Data Extraction
A data extraction tool that incorporates relevant items
(recommended by the Cochrane handbook for systematic
reviews of interventions [44]) will be used to extract and record
data from the studies. The descriptive characteristics of each
study, including citation, author details, year, country, study
design, sample size, participant composition (eg, percentage of
females), and statin indication (primary or secondary prevention)
will be summarized. Additionally, we will collect information
on adherence and persistence definitions and measurement
technique(s), as well as adherence and persistence rates and
reported predictive factors. If adherence is measured using more
than one technique, the average adherence will be calculated
and the results of various techniques will be extracted for a
sensitivity analysis. Studies evaluating the impact of an
intervention will only have baseline (or comparative control
group) results selected. We anticipate variations in the duration
of patients’ follow-up, and we will report adherence and
persistence rates for both short-term (eg, 3 months, 6 months,
12 months) and long-term (24 months or more, up to 5 years)
follow-ups, to the extent that available data allows. Individual
study data will be extracted separately by two members of the
team (RO and another team member) and compared to ascertain
consistency and reliability. Any discrepancies will be resolved
through consensus-based discussions among the reviewers.
Corresponding authors will be contacted via email for assistance
if missing or unclear data cannot be reliably extracted. Authors
that have not responded within a set period of time will be
declared unreachable.
Analyses
Adherence and persistence represent different aspects of
medication usage [28,29], so separate analyses of these outcomes
will be conducted. Adherence and persistence rates reported
from individual studies will be logit transformed using the
formula: x=logit (p)=In(p /1- p), where  p is the proportion of
patients who were considered to be adherent or persistent.
Meta-analyses will be performed using a random-effect model
weighted by the inverse variance. Results will be
back-transformed into proportion (using the formula
p=logit-1[x]=ex/ ex+1) to ensure comprehensive interpretation
of results [45]. Cases in which adherence or persistence are
reported only by distinct groups (ie, gender, age groupings) will
have subgroups included as separate terms in the meta-analyses.
For factors reported to be associated with adherence or
persistence, the odds ratios (ORs) along with 95% CIs will be
used for quantitative pooling. If the measures of association are
reported as other parameters (eg, relative risk and standard mean
difference), these will be converted to ORs. Instances in which
a study reports an insignificant association without data will
have an OR of 1 assigned. Log ORs and standard errors will be
combined using the generic inverse-variance method. For each
predictive factor, results will be quantitatively pooled, if reported
by a minimum of two studies. Results of meta-analyses will be
presented as forest plots. The level of heterogeneity resulting
from variations of effects from individual studies will be
assessed based on I2statistics. I2values of 30-60% may denote
moderate heterogeneity, 50-90% substantial heterogeneity, and
75-100% considerable heterogeneity [46]. We will evaluate the
presence of publication bias by assessing the asymmetry of
effect sizes in funnel plots using the trim-and-fill method [47],
and Egger’s regression tests will be used to quantify small study
effects [48]. Additionally, a leave-one-out sensitivity analysis
will be conducted by iteratively removing one study at a time
to assess the impact of each study on the overall pooled
adherence and persistence estimates [49]. Subgroup analyses
will be performed based on covariates such as study design,
country of origin, method used to estimate adherence, length
of patient follow-up, and statin indication. Meta-analyses will
be conducted using Comprehensive Meta-Analysis software
(version 3.0, Biostat, New Jersey).
Ethics and Dissemination
This study is based on published aggregate data. No identifiable
individual data will be utilized, making a formal ethical approval
unnecessary. This study has been registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) with reference number CRD42016053191. If
any aspect of the review is modified, this protocol will be
updated in the registry. This systematic review will form a
chapter of RO’s PhD thesis. The results of the study will also
be disseminated through publications in peer-reviewed journals
and presentations at relevant conferences and seminars.
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Results
The electronic database searches for relevant articles were
completed in December 2016. The searches resulted in retrieval
of over 10,000 articles. Removal of duplicates resulted in
approximately 8000 articles that are currently being screened.
The screening processes and analysis are expected to be
completed by June 2017.
Discussion
This systematic review, along with the potential to conduct
meta-analyses, will provide important information regarding
issues of adherence and persistence to statin therapy among
older patients. The population of the world is aging [21], and
most countries are expected to witness an expansion in the size
of elderly populations. The elderly often face the greatest
morbidity and mortality burden, making curative and preventive
therapies intended to improve survival, minimize morbidity,
and enhance quality of life extremely essential [50,51].
Enhancing adherence is one of the key ways of improving
medication effectiveness. The findings of this study are therefore
expected to inform the design of appropriate interventions that
will improve adherence to statin therapy among elderly patients,
so that optimal benefits can be accrued from such interventions.
Strengths and Limitations of Study
The strengths and limitations of this study are summarized in
Textbox 2.
Textbox 2. Study’s strengths and limitations.
• Appropriate search strategy has been designed in consultation with an information management specialist who is experienced in conducting
systematic reviews
• This study will be the first to evaluate statin adherence and persistence issues specific to older patients, and to compare variability across statin
indications
• Our study does not impose any restriction on time period or geographic location
• Non-English articles will be excluded from the review, which may introduce some bias
• Study assessments will involve reviewer judgements, which may introduce bias
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